Transformer-based long-term predictor of subthalamic beta activity in Parkinson’s disease

Competing Interest Statement

IUI is a Newronika S.p.A. consultant and shareholder and received funding for research activities from Newronika S.p.A. IUI received lecture honoraria and research funding from Medtronic Inc. IUI is Adjunct Professor at the Department of Neurology, NYU Grossman School of Medicine. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Clinical Trial

NCT04681534

Funding Statement

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The study was funded by the European Union - Next-Generation EU - NRRP M6C2 - Investment 2.1 Enhancement and strengthening of biomedical research in the NHS, and by the Fondazione Pezzoli per la Malattia di Parkinson. CP and IUI were supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Project-ID 424778381 - TRR 295. IUI was supported by a grant from New York University School of Medicine and The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders, which was made possible. With support from Marlene and Paolo Fresco. AM was supported by the Italian Ministry of Research, under the complementary actions to the NRRP "Fit4MedRob - Fit for Medical Robotics" Grant (# PNC0000007). AM was supported by the project "IMAD23ALM MAD: The etiopathological basis of gait derangement in Parkinson's disease: decoding locomotor network dynamics". SF and AM acknowledge the support of the BRIEF "Biorobotics Research and Innovation Engineering Facilities" project (Project identification code IR0000036) funded under the National Recovery and Resilience Plan (NRRP), Mission 4 Component 2 Investment 3.1 of Italian Ministry of University and Research funded by the European Union - Next-Generation EU.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study involving humans was conducted in accordance with the Declaration of Helsinki and approved by Milano Area 2 Ethics Committee (approval: 165-2020 and 93-2023bis). The study was conducted in accordance with the local legislation and institutional requirements. The participant provided written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes